Acute Myeloid Leukemia in Pediatrics

A special issue of Children (ISSN 2227-9067). This special issue belongs to the section "Pediatric Hematology & Oncology".

Deadline for manuscript submissions: closed (31 December 2020) | Viewed by 4075

Special Issue Editor


E-Mail Website
Guest Editor
Department of Pediatric Hematology and Oncology, Clinic of Pediatrics III, University Hospital Essen, 45147 Essen, Germany
Interests: acute myeloid leukemia; leukemogenesis; stem cell biology; gene therapy
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Given the still limited prognosis for children suffering from AML, I would like to propose a comprehensive Special Issue in Children entitled “Acute Myeloid Leukemia in Pediatrics”.
Although some cooperative childhood AML study groups have achieved survival rates of more than 70%, the prognosis in most parts of the world is still terribly low.
Therefore, continuous efforts in research, diagnostics and therapy are necessary to improve the outcome and cure rates in pediatric AML.
Merging the most recent results from basic and translational research with innovative treatment approaches, this Special Issue will give an excellent overview and may provide standards within a broad community.
The most recent developments in global cooperative projects highlight the urgent need to update and align the knowledge on all levels of research, diagnostics and therapy in pediatric AML.
This Special Issue should cover the latest results and standards regarding leukemic stem cell hierarchy and evolution, diagnostics, prognostic factors and successful treatment approaches in childhood AML. The encouraging results of cellular and immune therapies should be discussed. In addition, the current treatment options in relevant subgroups such as treatment-related AML or AML associated with predisposition syndromes should be included.
I believe that this will provide not only a valuable update on this topic but also a unique guideline for pediatricians worldwide.

Prof. Dr. Dirk Reinhardt
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Children is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2400 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • childhood leukemia
  • acute myeloid leukemia
  • leukemogenesis
  • risk factors
  • AML therapy

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

12 pages, 1248 KiB  
Article
Treatment Outcomes of Pediatric Acute Myeloid Leukemia in the Yeungnam Region: A Multicenter Retrospective Study of the Study Alliance of Yeungnam Pediatric Hematology–Oncology (SAYPH)
by Jae Min Lee, Eu Jeen Yang, Kyung Mi Park, Young-Ho Lee, Heewon Chueh, Jeong Ok Hah, Ji Kyoung Park, Jae Young Lim, Eun Sil Park, Sang Kyu Park, Heung Sik Kim, Ye Jee Shim, Jeong A. Park, Eun Jin Choi, Kun Soo Lee, Ji Yoon Kim and Young Tak Lim
Children 2021, 8(2), 109; https://doi.org/10.3390/children8020109 - 5 Feb 2021
Cited by 4 | Viewed by 2445
Abstract
Acute myeloid leukemia (AML) is the second most common pediatric leukemia, with a survival rate of 70%. In this retrospective study, we evaluated the treatment outcomes of pediatric AML among 144 patients diagnosed between 2000 and 2013. After induction, 80.6% of patients achieved [...] Read more.
Acute myeloid leukemia (AML) is the second most common pediatric leukemia, with a survival rate of 70%. In this retrospective study, we evaluated the treatment outcomes of pediatric AML among 144 patients diagnosed between 2000 and 2013. After induction, 80.6% of patients achieved complete remission (CR). The 5-year overall survival (OS) and event-free survival (EFS) rates were 58.8 ± 4.2% and 49.8 ± 4.2%, respectively. Based on the response to induction therapy, the 5-year OS was 66.9 ± 5.7% in patients with CR (p < 0.001). Ninety-nine patients with CR after induction therapy were examined, and their 5-year OS and EFS were 66.4 ± 4.9% and 56.3 ± 5.1%, respectively. The 5-year OS rates according to treatment were 59.9 ± 7.4% in the chemotherapy group and 72.3 ± 6.3% in the hematopoietic stem cell transplantation (HSCT) group (p = 0.089). The EFS was 50.1 ± 7.4% in the chemotherapy group and 61.7 ± 6.9% in the HSCT group (p = 0.098). OS and EFS according to cytogenetics were insignificant. Our findings confirmed that the response to induction treatment was important for survival and HSCT had no significant survival benefits compared with those of chemotherapy. Moreover, many early induction deaths under the age of 2 years were observed. Full article
(This article belongs to the Special Issue Acute Myeloid Leukemia in Pediatrics)
Show Figures

Figure 1

Back to TopTop